title: Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.
abstract: The incidence of thyroid cancer is growing at a rapid rate, with the majority of cases being differentiated thyroid cancers. Although a significant number of patients with localized disease are cured, a paucity of effective therapies currently exists for patients with recurrent and/or metastatic disease. The translational bridging of critical biologic insights into the pathogenesis of thyroid cancer and the clinical development of specific kinase inhibitors that disrupt these oncogenic pathways has led to exciting progress in clinical thyroid cancer research. This review will present the scientific rationale and clinical trial data gathered to date with kinase inhibitors in differentiated thyroid cancers.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. hoa@mskcc.org
authors.forename: Alan L
authors.initials: AL
authors.lastname: Ho
authors.forename: Eric
authors.initials: E
authors.lastname: Sherman
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002454:Cell Differentiation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases